References from scientific journals

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Haynes R, et al. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818. Circulation. 2018. PMID: 30002098 Clinical Trial.

RESULTS: In total, 207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline measured GFR was 34.0 (SE, 0.8) and 34.7 (SE, 0.8) mL/min/1.73 m(2), respectively. ...CONCLUSIONS: Over 12 months, sacubitril/valsartan has similar effects on kidney f …
RESULTS: In total, 207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline measured GFR was 34.0 (SE, …

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. Trachtman H, et al. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. J Am Soc Nephrol. 2018. PMID: 30361325 Free PMC article. Clinical Trial.

The FSGS partial remission end point was achieved in 28% of sparsentan-treated and 9% of irbesartan-treated patients (P=0.04). After 8 weeks of treatment, BP was reduced with sparsentan but not irbesartan, and eGFR was stable with both treatments. ...CONCLUSIONS: Pa …
The FSGS partial remission end point was achieved in 28% of sparsentan-treated and 9% of irbesartan-treated patients (P=0.04). After …

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.

Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, Gaze D, Kiotsekoglou A, Yuan L, Hu J, Foley C, Van Dyck L, Knight R, Clayton T, Swan L, Thomson JDR, Erdem G, Crossman D, Flather M; AIMS Investigators. Mullen M, et al. Lancet. 2019 Dec 21;394(10216):2263-2270. doi: 10.1016/S0140-6736(19)32518-8. Epub 2019 Dec 10. Lancet. 2019. PMID: 31836196 Free PMC article. Clinical Trial.

We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. ...Irbesartan was well tolerated with no observed differences in rates of serious adverse events. ...
We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. ...I …

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Oparil S, et al. J Clin Hypertens (Greenwich). 2001 Sep-Oct;3(5):283-91, 318. doi: 10.1111/j.1524-6175.2001.01136.x. J Clin Hypertens (Greenwich). 2001. PMID: 11588406 Free article. Clinical Trial.

The reduction of sitting cuff DBP with olmesartan (11.5 mm Hg), the primary efficacy variable of this study, was significantly greater than with losartan, valsartan, and irbesartan (8.2, 7.9, and 9.9 mm Hg, respectively). Reductions of cuff SBP with the four ARBs ranged fr …
The reduction of sitting cuff DBP with olmesartan (11.5 mm Hg), the primary efficacy variable of this study, was significantly greater than …

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE; ANSWER Study Organization. Ruggiero B, et al. Am J Kidney Dis. 2019 Sep;74(3):338-350. doi: 10.1053/j.ajkd.2019.01.029. Epub 2019 Apr 23. Am J Kidney Dis. 2019. PMID: 31027883 Clinical Trial.

SETTING & PARTICIPANTS: Between November 2013 and December 2014, we enrolled 53 patients with CKD with estimated glomerular filtration rates (eGFRs)>15mL/min/1.73m(2) and residual proteinuria with protein excretion0.5g/24h despite maximal tolerated ramipril and/or irbes …
SETTING & PARTICIPANTS: Between November 2013 and December 2014, we enrolled 53 patients with CKD with estimated glomerular filtration r …

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.

Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. Tromp J, et al. J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052. J Am Coll Cardiol. 2019. PMID: 31370950 Free article. Clinical Trial.

METHODS: Using data on patients with left ventricular ejection fraction 45% from 3 large HFpEF trials (TOPCAT [Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function], I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Fun …
METHODS: Using data on patients with left ventricular ejection fraction 45% from 3 large HFpEF trials (TOPCAT [Aldosterone Antagonist Therap …

Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.

Kuno T, Ueyama H, Fujisaki T, Briasouli A, Takagi H, Briasoulis A. Kuno T, et al. Am J Cardiol. 2020 Apr 15;125(8):1187-1193. doi: 10.1016/j.amjcard.2020.01.009. Epub 2020 Jan 30. Am J Cardiol. 2020. PMID: 32081366

Our search identified 5 eligible clinical trials (PEP-CHF, perindopril; CHARM-preserved, candesartan; I-PRESERVE, irbesartan; TOPCAT, spironolactone; PARAGON-HF, sacubitril-valsartan and valsartan) enrolling a total 10,523 on RAAS antagonists and 6,259 controls. ...
Our search identified 5 eligible clinical trials (PEP-CHF, perindopril; CHARM-preserved, candesartan; I-PRESERVE, irbesartan; TOPCAT, …

Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice.

Yisireyili M, Uchida Y, Yamamoto K, Nakayama T, Cheng XW, Matsushita T, Nakamura S, Murohara T, Takeshita K. Yisireyili M, et al. Brain Behav Immun. 2018 Mar;69:167-179. doi: 10.1016/j.bbi.2017.11.010. Epub 2017 Nov 16. Brain Behav Immun. 2018. PMID: 29155324

They were orally treated during the stress with either vehicle, 3 or 10 mg/kg/day irbesartan. Restraint stress resulted in colon inflammation with higher histological damage scores, increased expression of Nox4, TLR-4 and IL1-beta, accumulation of reactive oxygen species ( …
They were orally treated during the stress with either vehicle, 3 or 10 mg/kg/day irbesartan. Restraint stress resulted in colon infl …

Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol.

Chow CK, Atkins ER, Billot L, Chalmers J, Hillis GS, Hay P, Neal B, Nelson M, Patel A, Reid CM, Schlaich M, Usherwood T, Webster R, Rodgers A. Chow CK, et al. Am Heart J. 2021 Jan;231:56-67. doi: 10.1016/j.ahj.2020.09.017. Epub 2020 Oct 2. Am Heart J. 2021. PMID: 33017580 Free PMC article. Clinical Trial.

Participants will be randomized 1:1 and allocated to intervention therapy of a single pill (quadpill) containing irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or to control therapy of a single identical-appearing pill containing irbe …
Participants will be randomized 1:1 and allocated to intervention therapy of a single pill (quadpill) containing irbesartan 37.5 mg, …

Irbesartan (a comprehensive profile).

Darwish IA, Darwish HW, Bakheit AH, Al-Kahtani HM, Alanazi Z. Darwish IA, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:185-272. doi: 10.1016/bs.podrm.2020.07.004. Epub 2020 Aug 21. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461698 Review.

Irbesartan can be used alone or in combination with other antihypertensive agents (e.g., hydrochlorothiazide). ...Irbesartan exerts its action mainly via a selective blockade action on AT1 receptors and the consequent reduced pressor effect of angiotensin II. ...
Irbesartan can be used alone or in combination with other antihypertensive agents (e.g., hydrochlorothiazide). ...Irbesartan e …